Entropix Strengthens Board with Appointment of Experienced Non-Executive Director

Industry leader Dr David Pears joins the Entropix board and brings a wealth of expert knowledge in relation to specialty chemicals and technology commercialisation.

Entropix has recently appointed Dr David Pears to its board as Non-Executive Director. David has over 30 years’ senior experience in the chemical industry, spanning global multinational manufacturers to high-growth, early-stage ventures.

Following his PhD in Organic Chemistry, David joined ICI/Avecia leading research activities in polymer chemistry before becoming CTO and director of Reaxa. He subsequently became CTO at Revolymer /Itaconix and played a significant role in the flotation of the company on AIM. More recently he has been a director and advisor with G2O Water Technologies (now Evove), and Zentraxa.

Dr David Pears
Dr David Pears

Co-founder and CEO Dr Rob Rule said, “It’s a real pleasure to welcome David to Entropix. His extensive expertise and insights in the chemical industry will be invaluable for us as we continue to grow the company with our customers and partners in enzyme engineering and biocatalyst development.”

Dr David Pears said “I’m delighted to join the Entropix board. The company has some promising technologies to accelerate the development of enzymes using computational gene sequence analysis and directed evolution. I look forward to working with the founders and the whole Entropix team to commercialise these technologies in biocatalyst development, diagnostics, detergents and other sectors”.